Mr. Brian T. Dorsey has served in the Pharmaceutical and Biotechnology industries for over 20 years where he has provided high-level drug development, regulatory, and QC/QA leadership of pharmaceutical candidates from early development through FDA approval. He has held various senior management roles with Pharmaceutical and Biotechnology companies. Mr. Dorsey lives in the San Diego area with his family.

Mr. Dorsey is currently a Founding Partner at MagnaSci Ventures, a healthcare fund focused on investing in early stage life science companies. Additionally, Mr. Dorsey serves as Chief Development Officer for Apricus BioSciences and CEO of Po5 Pharma LLC where he and his team provide consulting services to the life science industry focused primarily on drug development and regulatory affairs. He serves on the Board of Directors for Neurana Pharmaceuticals, Cell Machines, Forge Therapeutics, and Tao Life Sciences as well as board observer for Oncternal Therapeutics, and MDRejuvena. He is a founder of Kalyra Pharmaceuticals and Septum Solutions. He also serves as an advisor to several small start-up companies in the San Diego area. Mr. Dorsey received his Master of Science in Executive Leadership and his B.A. in Chemistry from the University of San Diego.

Mr. Dorsey began his career as a Validation Engineer for Interpore International (now Biomet) working on dental implants and bone replacement harvested from coral. He ran the Compounding, Formulation, and In-Process Chemistry Lab for McGaw Laboratories (now B. Braun Medical), a large basic and specialty intravenous IV developer and manufacturer. Mr. Dorsey was Manager of Chemistry, Manufacturing, and Control for Chugai Biopharmaceuticals working to develop antisense oligonucleotides technology for HIV and oncology applications. Mr. Dorsey held several positions within the Agouron / Warner Lambert / Pfizer organizations prior to being named a Global Project Leader within Pfizer, leading development projects in the antiviral, oncology, and ophthalmology therapeutic areas. This included the development of a novel protease inhibitor for HIV. Mr. Dorsey served as Head of Biopharmaceutical Project Management of Baxter Bioscience (now Baxalta), a division of Baxter Healthcare Corporation working on hemophilia and other blood disorders such as protein C deficiency. Mr. Dorsey served as Head of Project Management, Medical Writing, and Library Services at Maxim Pharmaceuticals. His work there focused on the development of novel oncology therapies. Mr. Dorsey held several positions with Somaxon Pharmaceuticals (2005-2013) prior to being named Senior Vice President of Technical Operations and Regulatory Affairs where he focused on the development and commercialization of novel CNS related therapies including insomnia. Mr. Dorsey served as Senior Vice President of Research and Development and Chief Compliance Officer of Pernix Therapeutics Holding Inc. (acquirer of Somaxon) until his departure in late 2014.